285 related articles for article (PubMed ID: 31585986)
1. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
[TBL] [Abstract][Full Text] [Related]
2. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
Kato S; Takayama N; Takano H; Koretsune H; Koizumi C; Kunioka EI; Uchida S; Takahashi T; Yamamoto K
Eur J Pharmacol; 2018 Nov; 838():138-144. PubMed ID: 30179610
[TBL] [Abstract][Full Text] [Related]
3. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
Shinfuku A; Shimazaki T; Fujiwara M; Sato F; Watase H; Numazaki T; Kawakita Y; Mutoh M; Yamasaki H; Takayama N; Kato S; Sugimoto T; Maruyama J
Am J Nephrol; 2018; 48(3):157-164. PubMed ID: 30176654
[TBL] [Abstract][Full Text] [Related]
4. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
5. TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats.
Kato S; Yamamoto K; Uchida S; Takahashi T
Biol Pharm Bull; 2021; 44(11):1653-1661. PubMed ID: 34719642
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
7. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
Yasuoka Y; Izumi Y; Fukuyama T; Omiya H; Pham TD; Inoue H; Oshima T; Yamazaki T; Uematsu T; Kobayashi N; Shimada Y; Nagaba Y; Yamashita T; Mukoyama M; Sato Y; Wall SM; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164384
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin production by PDGFR-β(+) cells.
Gerl K; Nolan KA; Karger C; Fuchs M; Wenger RH; Stolt CC; Willam C; Kurtz A; Kurt B
Pflugers Arch; 2016 Aug; 468(8):1479-87. PubMed ID: 27220347
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Jain MR; Joharapurkar AA; Pandya V; Patel V; Joshi J; Kshirsagar S; Patel K; Patel PR; Desai RC
Drug Res (Stuttg); 2016 Feb; 66(2):107-12. PubMed ID: 26367279
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-β1 decreases erythropoietin production through repressing hypoxia-inducible factor 2α in erythropoietin-producing cells.
Shih HM; Pan SY; Wu CJ; Chou YH; Chen CY; Chang FC; Chen YT; Chiang WC; Tsai HC; Chen YM; Lin SL
J Biomed Sci; 2021 Nov; 28(1):73. PubMed ID: 34724959
[TBL] [Abstract][Full Text] [Related]
13. Effects of PHD and HSP90 on erythropoietin production in yak (Bos grunniens) renal interstitial fibroblast-like cells under hypoxia.
Cui Y; Li H; Yu SJ; Afedo SY; Bai XF
J Mol Histol; 2022 Apr; 53(2):395-411. PubMed ID: 35084636
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia Signaling Cascade for Erythropoietin Production in Hepatocytes.
Tojo Y; Sekine H; Hirano I; Pan X; Souma T; Tsujita T; Kawaguchi S; Takeda N; Takeda K; Fong GH; Dan T; Ichinose M; Miyata T; Yamamoto M; Suzuki N
Mol Cell Biol; 2015 Aug; 35(15):2658-72. PubMed ID: 26012551
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
16. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hasegawa S; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):331-338. PubMed ID: 30067604
[TBL] [Abstract][Full Text] [Related]
18. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
19. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia.
Kapitsinou PP; Liu Q; Unger TL; Rha J; Davidoff O; Keith B; Epstein JA; Moores SL; Erickson-Miller CL; Haase VH
Blood; 2010 Oct; 116(16):3039-48. PubMed ID: 20628150
[TBL] [Abstract][Full Text] [Related]
20. Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin.
Kobayashi H; Liu Q; Binns TC; Urrutia AA; Davidoff O; Kapitsinou PP; Pfaff AS; Olauson H; Wernerson A; Fogo AB; Fong GH; Gross KW; Haase VH
J Clin Invest; 2016 May; 126(5):1926-38. PubMed ID: 27088801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
